Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease

Stem Cells

Volumn 31, Issue 3, 2013, Pages 592-601

  Ringdén, Olle ^a   Erkers, Tom ^a   Nava, Silvia ^a   Uzunel, Mehmet ^a   Iwarsson, Erik ^b   Conrad, Réka ^a   Westgren, Magnus ^b   Mattsson, Jonas ^a   Kaipe, Helen ^a  

^a Center for Allogeneic Stem Cell Transplantation   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Decidua; Fetal membrane cells; Graft versus host disease; Hematopoietic stem cell transplantation; Mesenchymal stromal cells; Regenerative medicine

Indexed keywords

5' NUCLEOTIDASE; ALPHA4 INTEGRIN; AMPHOTERICIN B; BETA1 INTEGRIN; BUDESONIDE; CYCLOSPORIN A; ENDOGLIN; HERMES ANTIGEN; METHOTREXATE; PREDNISOLONE; PSORALEN; RAPAMYCIN; TACROLIMUS; THY 1 ANTIGEN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; FEMALE; FETUS MEMBRANE; FETUS MEMBRANE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; KARYOTYPE; KARYOTYPING; LUNG INFILTRATE; MALE; MICROSATELLITE MARKER; STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE; TOTAL PARENTERAL NUTRITION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; VERNER MORRISON SYNDROME;

ADOLESCENT; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PLACENTA; PREGNANCY; REGENERATIVE MEDICINE;

EID: 84874920824     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1314     Document Type: Article

References (75)

1. Mincheva-Nilsson L. Immune cells and molecules in pregnancy: Friends or foes to the fetus? Exp Rev Clini Immunol 2006;2: 457-470.
2. Trowsdale J, Betz AG. Mother's little helpers: Mechanisms of maternal- fetal tolerance. Nat Immunol 2006;7: 241-246.
3. Ilancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: A source of stem cells for tissue regeneration and repair? Placenta 2009; 30: 2-10.
4. Karlsson H, Erkers T, Nava S et al. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clini Exp Immunol 2012;167: 543-555.
5. Parolini O, Alviano F, Bagnara GP et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 2008;26: 300-311.
6. Portmann-Lanz CB, Schoeberlein A, Huber A et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstetrics Gynecol 2006;194: 664-673.
7. Roelen DL, van der Mast BJ, in't Anker PS et al. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol 2009;70: 16-23.
8. Kesting MR, Wolff KD, Hohlweg-Majert B et al. The role of allogenic amniotic membrane in burn treatment. J Burn Care Res 2008; 29: 907-916.
9. Fernandes M, Sridhar MS, Sangwan VS et al. Amniotic membrane transplantation for ocular surface reconstruction. Cornea 2005;24: 643-653.
10. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49: 511-533.
11. Hoogerbrugge PM, Brouwer OF, Bordigoni P et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995;345: 1398-1402.
12. Ringden O. Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res 2007;97C: 25-60.
13. van Bekkum DW. Graft-versus-host disease. New York: Marcel Dekker, Inc., 1985.
14. Storb R, Thomas ED. Graft-versus-host disease in dog and man: The Seattle experience. Immunol Rev 1985;88: 215-238.
15. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81: 1390-1397.
16. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371: 1579-1586.
17. von Bonin M, Stolzel F, Goedecke A et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl 2009;43: 245-251.
18. Lucchini G, Introna M, Dander E et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graftversus- host disease in a pediatric population. Biol Blood Marrow Transplant 2010;16: 1293-1301.
19. Kebriaei P, Isola L, Bahceci E et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graftversus- host disease. Biol Blood Marrow Transplant 2009;15: 804-811.
20. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30: 42-48.
21. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic Tcell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75: 389-397.
22. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994;56: 283-294.
23. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57: 11-20.
24. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815-1822.
25. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000;28: 875-884.
26. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143-147.
27. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262: 509-525.
28. Barlow S, Brooke G, Chatterjee K et al. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008;17: 1095-1107.
29. Alviano F, Fossati V, Marchionni C et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 2007;7: 11.
30. Sakuragawa N, Kakinuma K, Kikuchi A et al. Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. J Neurosci Res 2004;78: 208-214.
31. Karahuseyinoglu S, Cinar O, Kilic E et al. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells 2007;25: 319-331.
32. Winiarski J, Mattsson J, Gustafsson A et al. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatric Transplant 1998;2: 150-156.
33. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994;83: 2723-2730.
34. Remberger M, Svahn BM, Mattsson J et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004;78: 122-127.
35. Storb R, Deeg HJ, Fisher L et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials. Blood 1988;71: 293-298.
36. Ringden O, Remberger M, Persson U et al. Similar incidence of graftversus- host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15: 619-625.
37. Luznik L, O'Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14: 641-650.
38. Ringden O, Remberger M, Dahllof G et al. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. Eur J Haematol 2011; 87: 503-509.
39. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graftversus- host disease in human recipients of marrow from HL-Amatched sibling donors. Transplantation 1974;18: 295-304.
40. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31: 890-896.
41. Snover DC, Weisdorf SA, Vercellotti GM et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 1985;16: 387-392.
42. Fang B, Song YP, Li N et al. Resolution of refractory chronic autoimmune thrombocytopenic purpura following mesenchymal stem cell transplantation: A case report. Transplant Proc 2009;41: 1827-1830.
43. Liang J, Zhang H, Hua B et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009;15: 644-646.
44. Garcia-Olmo D, Garcia-Arranz M, Herreros D et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48: 1416-1423.
45. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow- derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011;60: 788-798.
46. Garcia-Olmo D, Herreros D, Pascual I et al. Expanded adiposederived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009;52: 79-86.
47. Mannon PJ. Remestemcel-L: Human mesenchymal stem cells as an emerging therapy for Crohn's disease. Exp Opin Biol Ther 2011;11: 1249-1256.
48. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010;59: 1662-1669.
49. Chen LW, Tredget EE, Wu PYG et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. Plos One 2008;3.
50. Falanga V, Iwamoto S, Chartier M et al. Autologous bone marrowderived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007;13: 1299-1312.
51. Almeida-Porada G, Flake AW, Glimp HA et al. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 1999;27: 1569-1575.
52. Ball LM, Bernardo ME, Roelofs H et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110: 2764-2767.
53. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11: 389-398.
54. Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21: 1733-1738.
55. Meuleman N, Tondreau T, Ahmad I et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells Dev 2009;18: 1247-1252.
56. Brooke G, Rossetti T, Pelekanos R et al. Manufacturing of human placenta- derived mesenchymal stem cells for clinical trials. Brit J Haematol 2009;144: 571-579.
57. Kanematsu D, Shofuda T, Yamamoto A et al. Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta. Differentiation 2011;82: 77-88.
58. Tamagawa T, Oi S, Ishiwata I et al. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Hum Cell 2007;20: 77-84.
59. Tamagawa T, Ishiwata I, Sato K et al. Induced in vitro differentiation of pancreatic-like cells from human amnion-derived fibroblast-like cells. Hum Cell 2009;22: 55-63.
60. von Bahr L, Sundberg B, Lonnies L et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18: 557-564.
61. Ringden O, Le Blanc K. Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells. Biol Blood Marrow Transplant 2006;12: 693-694.
62. Ringden O. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease and graft failure after hematopoietic stem cell transplantation and future challenges. In: Mesenchymal Stem Cell Therapy. Chase LG, Vemuri MC (eds.). Springer Verlag, Humana Press 2013, pp. 173-206.
63. Ringden O, Leblanc K. Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplant 2011;46: 1158-1160.
64. Moll G, Duprez IR, von Bahr L et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30: 1565-1574.
65. Chen L, Tredget EE, Liu C et al. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. Plos One 2009;4:e7119.
66. Sasaki M, Abe R, Fujita Y et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008;180: 2581-2587.
67. Wu GD, Nolta JA, Jin YS et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003;75: 679-685.
68. Ringden O, Uzunel M, Sundberg B et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21: 2271-2276.
69. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76: 1208-1213.
70. English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009;156: 149-160.
71. Chen L, Tredget EE, Wu PY et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. Plos One 2008;3:e1886.
72. Maggini J, Mirkin G, Bognanni I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory- like profile. Plos One 2010;5:e9252.
73. Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15: 42-49.
74. Ringden O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985;40: 39-44.
75. Bernardo ME, Ball LM, Cometa AM et al. Co-infusion of ex vivoexpanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011;46: 200-207.